{"id":39932,"date":"2026-10-21T09:19:00","date_gmt":"2026-10-21T13:19:00","guid":{"rendered":"https:\/\/www.drugpatentwatch.com\/blog\/?p=39932"},"modified":"2026-10-17T07:24:26","modified_gmt":"2026-10-17T11:24:26","slug":"philippines-drug-patent-expiration-why-the-us-date-is-the-wrong-clock","status":"publish","type":"post","link":"https:\/\/www.drugpatentwatch.com\/blog\/philippines-drug-patent-expiration-why-the-us-date-is-the-wrong-clock\/","title":{"rendered":"Philippines Drug Patent Expiration: Why the US Date Is the Wrong Clock"},"content":{"rendered":"\n
\"\"<\/figure>\n\n\n\n

Pfizer lost US exclusivity on Lipitor on November 30, 2011. [1] The EU compound patent for the same drug expired in the same month, but pediatric extensions pushed exclusivity in most major European markets to May 2012. [1] One drug produced two different market-opening dates within six months of each other, in two markets with mature patent systems.<\/p>\n\n\n\n

The Philippines adds more variation. It has a flat 20-year patent term, no patent term extension, no patent linkage, and a special rule that limits patents on new forms of known drugs. [8][4][3] A US expiration date is one input to the Philippine question. It is never the answer.<\/p>\n\n\n\n

This article compares the two patent clocks, builds a scenario model with stated assumptions, and reviews three real records: the Lipitor settlement, a Philippine Supreme Court case on Unasyn, and a Philippine patent cancellation on amoxicillin-clavulanate. It was prepared in October 2026. Laws and agency practice can change, so confirm current status with the Intellectual Property Office of the Philippines (IPOPHL) and Philippine counsel before you act on any date.<\/p>\n\n\n\n

The Short Answer: Does a US Patent Expiration Date Tell You When a Drug Opens in the Philippines?<\/strong><\/h2>\n\n\n\n

No. A US expiration date tells you when one US patent ends. It does not tell you whether a Philippine counterpart exists, when it expires, whether it was cancelled, or whether the Philippine regulator will register a generic before that date.<\/p>\n\n\n\n

What Does the US Date Include That the Philippine Date Does Not?<\/strong><\/h3>\n\n\n\n

A US patent can carry patent term adjustment for Patent Office delay and patent term extension for FDA review time. [5][6] FDA can also add six months of pediatric exclusivity. [7] The Philippines has none of these three tools. [8]<\/p>\n\n\n\n

Four Points to Remember<\/strong><\/h3>\n\n\n\n
    \n
  • The Philippine term is 20 years from the filing date. For a PCT application, the clock starts at the international filing date. [9]<\/li>\n\n\n\n
  • No Philippine rule extends that term for regulatory delay or pediatric studies. [8]<\/li>\n\n\n\n
  • The Philippine FDA can register a generic without checking patents. [4]<\/li>\n\n\n\n
  • Philippine law excludes a new form of a known drug from patentability unless the form enhances known efficacy. [3]<\/li>\n<\/ul>\n\n\n\n

    The Six Findings That Matter<\/strong><\/h2>\n\n\n\n

    Each finding below is stated so that you can quote it without the rest of the article. Documented facts carry a source. Calculated figures are labeled as analysis.<\/p>\n\n\n\n

      \n
    1. Philippine patents have a uniform 20-year term, and the Philippines has no supplementary protection certificate or pediatric extension. [8]<\/li>\n\n\n\n
    2. A US patent can run past 20 years from filing through patent term adjustment under 35 U.S.C. 154(b) and patent term extension under 35 U.S.C. 156. [5][6]<\/li>\n\n\n\n
    3. The Philippines has no patent linkage. The FDA can process a registration without checking for patents, and it does not notify patentees. [4]<\/li>\n\n\n\n
    4. Section 22.1 of the Philippine IP Code, as amended by Republic Act 9502, excludes the mere discovery of a new form or new property of a known substance unless it enhances known efficacy. [3]<\/li>\n\n\n\n
    5. Pfizer’s Lipitor family had patent categories expiring from 2010 through 2018 in the US. Analysis: that is an eight-year spread inside one product. [10]<\/li>\n\n\n\n
    6. In 2024, IPOPHL reported 2,063 patent grants. Analysis: 94.9 percent went to non-resident applicants. [11]<\/li>\n<\/ol>\n\n\n\n

      Methodology: What We Analyzed and What We Did Not<\/strong><\/h2>\n\n\n\n

      This section states the scope of the analysis so that a reader can reproduce it.<\/p>\n\n\n\n

      What Data Did We Use?<\/strong><\/h3>\n\n\n\n

      We used four groups of records. The first group is statute and agency text: the Philippine IP Code as amended by Republic Act 9502, 35 U.S.C. 154 and 156, and FDA exclusivity guidance. The second group is the 2026 Chambers practice guide for the Philippines. The third group is IPOPHL filing and grant statistics for 2020 to 2024, as reproduced on the WIPO Centre for the Study of Patent Information page. The fourth group is three case records: the Pfizer and Ranbaxy settlement, Phil. Pharmawealth v. Pfizer, and OEP Philippines v. SmithKline Beecham.<\/p>\n\n\n\n

      How Did We Select Records?<\/strong><\/h3>\n\n\n\n

      We selected records that show a gap between a US date and a local date, or that show how Philippine rules differ from US rules. We did not select records by drug sales or by therapeutic area. We did not remove duplicates because we did not merge databases.<\/p>\n\n\n\n

      What Are the Limits?<\/strong><\/h3>\n\n\n\n

      We did not count Philippine pharmaceutical patents drug by drug. We did not query the IPOPHL patent database for individual drug families. The model in this article uses an illustrative drug, not a real product. The IPOPHL statistics page does not give pendency figures or pharmaceutical-specific counts. [11]<\/p>\n\n\n\n

      How Do We Label Documented Facts and Analysis?<\/strong><\/h4>\n\n\n\n

      A documented fact has a numbered source next to it. A figure we calculated from documented inputs is marked “analysis.” We did not present any calculated figure as a reported statistic.<\/p>\n\n\n\n

      Definitions: Patent Term, Linkage, and the Bolar Exception<\/strong><\/h2>\n\n\n\n

      What Is a Patent Term?<\/strong><\/h3>\n\n\n\n

      A patent term is the period in which a patent owner can exclude others. In both the US and the Philippines, the base term is 20 years from the filing date. [5][9]<\/p>\n\n\n\n

      What Is Patent Linkage?<\/strong><\/h3>\n\n\n\n

      Patent linkage ties drug approval to patent status. In the US, the generic applicant must certify against listed patents, and a patent suit can delay approval for 30 months. [12] The Philippines has no such system. [4]<\/p>\n\n\n\n

      What Is the Bolar Exception?<\/strong><\/h3>\n\n\n\n

      The Bolar exception lets a generic company use a patented drug before expiry to prepare a regulatory filing. The name comes from Roche v. Bolar, 733 F.2d 858, where the US Federal Circuit rejected Bolar’s experimental-use defense. [13] Congress then wrote the exception into US law, and the Supreme Court later read it to cover preclinical use in Merck KGaA v. Integra Lifesciences, 545 U.S. 193 (2005). [13]<\/p>\n\n\n\n

      What Is the Section 22 Exclusion?<\/strong><\/h3>\n\n\n\n

      Section 22 is the Philippine rule on non-patentable inventions. For drugs and medicines, it excludes a new form or new property of a known substance that does not enhance known efficacy. [3]<\/p>\n\n\n\n

      How the US Patent Clock Runs<\/strong><\/h2>\n\n\n\n

      What Is the Base Term of a US Drug Patent?<\/strong><\/h3>\n\n\n\n

      A US patent ends 20 years from the filing date of the application. If the application claims an earlier application under the relevant statutes, the 20 years run from the earliest such date. [5] For a patent from an international application, the clock starts at the international filing date.<\/p>\n\n\n\n

      How Does Patent Term Adjustment Work?<\/strong><\/h3>\n\n\n\n

      The Patent Office adds one day of term for each day it misses a statutory deadline. The deadlines include 14 months for a first action and three years for issuance. [5] The adjustment only compensates for office delay. It does not depend on FDA review.<\/p>\n\n\n\n

      How Does Patent Term Extension Work for Drugs?<\/strong><\/h3>\n\n\n\n

      Section 156 restores part of the time a drug spends in FDA review. The extension cannot exceed five years. [6] The extension counts one-half of the testing phase and all of the approval phase. [6] Only one patent can be extended for a given regulatory review period. [6]<\/p>\n\n\n\n

      What Is the 14-Year Cap?<\/strong><\/h4>\n\n\n\n

      The remaining patent term after approval, plus the extension, cannot exceed 14 years. [6] For many drugs, this cap sets the final US expiration date. The model later in this article uses the cap.<\/p>\n\n\n\n

      Which FDA Exclusivities Run Beside Patents?<\/strong><\/h3>\n\n\n\n

      FDA lists new chemical entity exclusivity at five years, new clinical investigation exclusivity at three years, and orphan drug exclusivity at seven years. [7] Pediatric exclusivity adds six months to existing patents and exclusivities. [7] Chambers reports no specific data or market exclusivity rules in the Philippines for orphan or pediatric medicines, new indications, or combinations. [4] Republic Act 9502 directs the IPOPHL to issue rules that protect submitted test data from unfair commercial use. [3]<\/p>\n\n\n\n

      What Is the Paragraph IV Route and the 30-Month Stay?<\/strong><\/h4>\n\n\n\n

      A Paragraph IV certification states that a listed patent is invalid or will not be infringed. [12] If the patent owner sues within 45 days of notice, approval can be delayed until 30 months after the notice, subject to the statute. [12] This is a US procedure. It has no Philippine counterpart.<\/p>\n\n\n\n

      How the Philippine Patent Clock Runs<\/strong><\/h2>\n\n\n\n

      What Is the Term of a Philippine Drug Patent?<\/strong><\/h3>\n\n\n\n

      Chambers reports a “uniform 20-year term” for all patents in the Philippines, regardless of invention type, applicant, or length of regulatory review. [8] For a PCT application, IPOPHL practice counts 20 years from the international filing date. [9]<\/p>\n\n\n\n

      Does the Philippines Have a Supplementary Protection Certificate?<\/strong><\/h4>\n\n\n\n

      No. Chambers states that the Philippines has no SPC or similar extension system. [8] Pediatric extensions are also unavailable. A patent expires at 20 years even if pediatric studies were done. [8]<\/p>\n\n\n\n

      When Must a PCT Applicant Enter the Philippines?<\/strong><\/h3>\n\n\n\n

      The national phase deadline is 30 months from the priority date. [9] A one-month extension is available for a fee. [9] The applicant must request substantive examination within six months of national phase entry, or the application is deemed withdrawn. [9]<\/p>\n\n\n\n

      This deadline matters for opportunity screening. If a US innovator never entered the Philippine national phase, no Philippine patent exists for that family. The US expiration date then has no bearing on the Philippine market. The same logic applies to a family where the applicant let the application lapse.<\/p>\n\n\n\n

      What Do Annual Fees Tell You About Patent Status?<\/strong><\/h4>\n\n\n\n

      The first annual fee is due four years after the international publication date. Later fees fall due on each anniversary. [9] An unpaid annual fee is a status signal that an analyst should check in the IPOPHL record.<\/p>\n\n\n\n

      Does a Late Philippine Grant Extend the Term?<\/strong><\/h3>\n\n\n\n

      No source we reviewed gives the Philippines a mechanism that adds term for examination delay. [8] The term runs from filing. A long examination reduces the enforceable life of the patent. The OEP Philippines record below shows a patent that issued on May 5, 2005 from an application number carrying a 1996 prefix. [14]<\/p>\n\n\n\n

      US vs. Philippines: Rule-by-Rule Patent Clock Comparison<\/strong><\/h2>\n\n\n\n

      The table below puts the main timing rules side by side. It is an original organization of the sources shown in each row.<\/p>\n\n\n\n

      Rule<\/th>United States<\/th>Philippines<\/th>Source<\/th><\/tr><\/thead>
      Base patent term<\/td>20 years from filing<\/td>20 years from filing; PCT counted from international filing date<\/td>[5][8][9]<\/td><\/tr>
      Delay-based adjustment<\/td>Yes, patent term adjustment<\/td>None found in sources reviewed<\/td>[5][8]<\/td><\/tr>
      Regulatory-review extension<\/td>Up to 5 years, 14-year cap after approval<\/td>None (no SPC)<\/td>[6][8]<\/td><\/tr>
      Pediatric extension<\/td>6 months added to patents and exclusivities<\/td>Unavailable<\/td>[7][8]<\/td><\/tr>
      New chemical entity exclusivity<\/td>5 years<\/td>Not reported in the sources reviewed; RA 9502 directs rules against unfair commercial use of submitted data<\/td>[7][4][3]<\/td><\/tr>
      Patent linkage<\/td>Yes, Paragraph IV and 30-month stay<\/td>No<\/td>[12][4]<\/td><\/tr>
      Pre-expiry testing for approval<\/td>Yes (Bolar, 35 U.S.C. 271(e)(1))<\/td>Yes (Section 72.4 of the IP Code)<\/td>[13][3]<\/td><\/tr>
      Limit on new-form patents<\/td>No drug-specific bar<\/td>Section 22.1 efficacy test<\/td>[3][2]<\/td><\/tr>
      Parallel imports of drugs<\/td>Not addressed here<\/td>Permitted if the owner first sold the product anywhere<\/td>[3][4]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

      Scenario Analysis: How Far Apart Can the US and Philippine Dates Be?<\/strong><\/h2>\n\n\n\n

      This section is a model. It uses a fictional drug and assumptions that we state in full. It is not a forecast for any real product.<\/p>\n\n\n\n

      Illustrative Model: Drug X<\/strong><\/h3>\n\n\n\n

      What Are the Assumptions?<\/strong><\/h4>\n\n\n\n
        \n
      • The international filing date is March 1, 2012. The US and Philippine applications both start from this date.<\/li>\n\n\n\n
      • The US Patent Office grants 450 days of patent term adjustment.<\/li>\n\n\n\n
      • FDA approves Drug X on March 1, 2020.<\/li>\n\n\n\n
      • The regulatory review period supports an extension long enough that the 14-year cap decides the result.<\/li>\n<\/ul>\n\n\n\n

        What Are the Results?<\/strong><\/h4>\n\n\n\n

        Analysis: the base expiry is March 1, 2032. With 450 days of adjustment, the US patent would end on May 25, 2033. The 14-year cap from approval allows an end date of March 1, 2034. The extension needed to reach the cap is about 280 days, or 9.2 months, which sits well inside the five-year limit. If pediatric exclusivity applies, the US exclusivity end moves to September 1, 2034. The Philippine patent for the same family ends March 1, 2032.<\/p>\n\n\n\n

        Item<\/th>Date<\/th>Basis<\/th><\/tr><\/thead>
        International filing date<\/td>March 1, 2012<\/td>Assumption<\/td><\/tr>
        Base 20-year expiry (US and Philippines)<\/td>March 1, 2032<\/td>Calculation [5][9]<\/td><\/tr>
        US expiry after 450 days of adjustment<\/td>May 25, 2033<\/td>Calculation [5]<\/td><\/tr>
        US expiry at the 14-year cap<\/td>March 1, 2034<\/td>Calculation [6]<\/td><\/tr>
        US exclusivity end with pediatric add-on<\/td>September 1, 2034<\/td>Calculation [7]<\/td><\/tr>
        Philippine expiry<\/td>March 1, 2032<\/td>Calculation [8]<\/td><\/tr>
        Gap, US cap vs. Philippines<\/td>24 months<\/td>Calculation<\/td><\/tr>
        Gap, US pediatric end vs. Philippines<\/td>30 months<\/td>Calculation<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        In this model, a US-based screen would show a market opening in 2034. The Philippine compound patent ends two years earlier. The size of the gap depends on the review period and the pediatric studies. A drug with a shorter FDA review gets a smaller gap.<\/p>\n\n\n\n

        What Happens If No Philippine Patent Exists for the Drug?<\/strong><\/h3>\n\n\n\n

        If no Philippine patent was filed or granted for the family, no Philippine patent bars a generic. The timing then depends on regulatory approval, not on patent status. The Philippine FDA can register a generic without checking for patents. [4] A US expiration date has no effect on this case.<\/p>\n\n\n\n

        What Happens If the Philippine Patent Covers Only a New Salt or Polymorph?<\/strong><\/h3>\n\n\n\n

        A later-filed patent on a salt or polymorph would start its own 20-year clock from its own filing date. Section 22.1 treats salts, polymorphs, and similar derivatives as the same substance unless they differ significantly in efficacy. [3][2] If the office grants the patent, it protects that form only. A competitor can then work around it with the original form, if the compound patent has expired. If the office refuses the patent, the later date never appears in the record.<\/p>\n\n\n\n

        What Happens If the Philippine Patent Is Cancelled?<\/strong><\/h3>\n\n\n\n

        Cancellation moves the opening date to the date the decision becomes final. The OEP record in this article shows a cancellation that became final on October 7, 2010, for a patent granted on May 5, 2005. [14] Analysis: that is 5.4 years after grant.<\/p>\n\n\n\n

        Scenario<\/th>Philippine barrier<\/th>Opening date driver<\/th><\/tr><\/thead>
        A. No Philippine filing or grant<\/td>None<\/td>Regulatory approval<\/td><\/tr>
        B. Compound patent granted<\/td>Patent to 20 years from filing<\/td>Philippine expiry date<\/td><\/tr>
        C. Salt or polymorph patent granted<\/td>That form only<\/td>Form-specific expiry, plus design-around options<\/td><\/tr>
        D. Patent cancelled<\/td>None after final decision<\/td>Date the cancellation is final<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        Section 22: The Philippine Rule on Secondary Drug Patents<\/strong><\/h2>\n\n\n\n

        What Does the Text Say?<\/strong><\/h3>\n\n\n\n

        Republic Act 9502 amended the IP Code to exclude, in the case of drugs and medicines, “the mere discovery of a new form or new property of a known substance which does not result in the enhancement of the known efficacy of that substance.” [3] The Act was approved in 2008 and took effect 15 days after publication in two national papers. [3]<\/p>\n\n\n\n

        How Does IPOPHL Examine These Claims?<\/strong><\/h3>\n\n\n\n

        Spruson and Ferguson reports that the QUAMA Guide applies the doctrine of inherency at the eligibility stage. An examiner asks whether the claim is a mere discovery that follows necessarily from the prior art. If it does, the claim is not eligible. Only eligible claims move on to novelty and inventive step. [2]<\/p>\n\n\n\n

        Is Enhanced Efficacy Enough?<\/strong><\/h4>\n\n\n\n

        No. The same source says that the new form must be non-inherent, and the enhanced efficacy must also be non-inherent. The enhancement must be unexpected. Efficacy can cover bioavailability, stability, or solubility if the specification supports the data. Improved thermodynamic stability and lower hygroscopicity are treated as inherent to a polymorph and do not count. [2]<\/p>\n\n\n\n

        What Does Section 22 Mean for Patent-Family Strategy?<\/strong><\/h3>\n\n\n\n

        A US patent family often includes later patents on salts, crystalline forms, and formulations. Section 22 makes the Philippine counterpart of such a patent harder to obtain. An analyst who counts US family members and assumes the same number in the Philippines will overstate the Philippine barrier. The count needs to start from the IPOPHL record.<\/p>\n\n\n\n

        Case Study: Lipitor Shows Why One Date Fails in Mature Markets<\/strong><\/h2>\n\n\n\n

        What Were the Lipitor Patent Dates?<\/strong><\/h3>\n\n\n\n

        When Pfizer and Ranbaxy announced their settlement on June 18, 2008, the announcement listed four groups of atorvastatin patents. [10] The table organizes those dates.<\/p>\n\n\n\n

        Patent category<\/th>US expiry<\/th>Source<\/th><\/tr><\/thead>
        Basic compound patent<\/td>2010<\/td>[10]<\/td><\/tr>
        Enantiomer patent<\/td>2011<\/td>[10]<\/td><\/tr>
        Process and crystalline form patents<\/td>2016 and 2017<\/td>[10]<\/td><\/tr>
        Combination patent (atorvastatin-amlodipine)<\/td>2018<\/td>[10]<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        Analysis: the US family spans eight years, from 2010 to 2018. The US generic entry date was November 30, 2011, which Pfizer reported as its loss of US exclusivity. [1] The announcement gives only the year for the compound patent. Analysis: the gap from compound expiry to US generic entry is therefore between 11 and 23 months.<\/p>\n\n\n\n

        How Did the Settlement Handle Other Countries?<\/strong><\/h3>\n\n\n\n

        The settlement did not use one date. Ranbaxy received licenses with varying dates in Canada, Belgium, the Netherlands, Germany, Sweden, Italy, and Australia. Disputes ended in Malaysia, Brunei, Peru, and Vietnam. Litigation continued in Finland, Spain, Portugal, Denmark, and Romania. [10] Each country had its own patent record and its own outcome.<\/p>\n\n\n\n

        Is the Philippines Named in the Settlement?<\/strong><\/h4>\n\n\n\n

        No. The announcement does not mention the Philippines. [10] The Lipitor record is useful for method, not for a Philippine date. It shows that a global drug has country-level dates, set by country-level patents and country-level deals.<\/p>\n\n\n\n

        Philippine Case Records: Unasyn and Amoxicillin-Clavulanate<\/strong><\/h2>\n\n\n\n

        What Did the Supreme Court Decide in Phil. Pharmawealth v. Pfizer?<\/strong><\/h3>\n\n\n\n

        Pfizer owned a patent on sulbactam ampicillin, sold as Unasyn. It sued Pharmawealth for patent infringement after Pharmawealth bid to supply the drug to hospitals. [15] The patent was registered on July 16, 1987, and expired 17 years later, on July 16, 2004. [15] The Supreme Court held that the Court of Appeals erred when it issued a temporary restraining order after that date. [15] It also found forum shopping, because Pfizer ran two actions with the same parties, rights, and relief. [15]<\/p>\n\n\n\n

        What Term Rule Applied in That Case?<\/strong><\/h4>\n\n\n\n

        The court applied Republic Act 165, under which exclusive rights last for the patent term of 17 years from registration. [15] The current rule is a 20-year term. [8] Analysis: the 1987 patent ran 17 years from grant, while a patent filed today runs 20 years from filing. Analysts who use old Philippine patents as models need to check which statute governed the grant.<\/p>\n\n\n\n

        The Supreme Court decided the case on November 17, 2010. [16] Analysis: that is about 6.3 years after the patent expired. The case shows that a patent dispute can outlast the patent.<\/p>\n\n\n\n

        What Does OEP Philippines v. SmithKline Beecham Show?<\/strong><\/h3>\n\n\n\n

        SmithKline Beecham held Philippine Patent No. 1-1996-52993, titled “Method of Treatment,” which issued on May 5, 2005. The claims cover a combination of amoxicillin trihydrate and potassium clavulanate. [14] OEP Philippines filed a cancellation petition on February 22, 2008, as IPC No. 11-2008-00048. [14]<\/p>\n\n\n\n

        The Bureau of Legal Affairs dismissed that petition on March 5, 2012. It did so because an earlier case, IPC No. 11-2006-000241, had already cancelled the patent. The Office of the Director General dismissed the appeal in that earlier case on September 16, 2010, and the decision became final on October 7, 2010. [14] The order does not analyze novelty, inventive step, or Section 22. [14]<\/p>\n\n\n\n

        What Does the Record Show About Pendency?<\/strong><\/h4>\n\n\n\n

        The patent number carries a 1996 prefix and the issue date is 2005. Analysis: if the prefix reflects the filing year, the application took about nine years to issue. A 20-year term from a 1996 filing would end in 2016. The patent was cancelled in 2010, so it never reached that date.<\/p>\n\n\n\n

        No Linkage: What Reaches the Philippine Market Without a Patent Check<\/strong><\/h2>\n\n\n\n

        Does the Philippine FDA Check Patents Before Registering a Generic?<\/strong><\/h3>\n\n\n\n

        No. Chambers reports that the Philippines eliminated patent linkage in 2006 and removed IP matters from FDA jurisdiction. The FDA can process registrations without checking for relevant patents, and it need not consider a valid patent even if it knows of one. [4] Patentees are not notified. They must watch FDA filings themselves. [4]<\/p>\n\n\n\n

        Can a Generic Company Test Before the Patent Expires?<\/strong><\/h3>\n\n\n\n

        Yes. Section 72.4 of the IP Code, added by Republic Act 9502, allows testing, using, making, or selling a patented invention, including related data, solely for purposes reasonably related to the development and submission of information for regulatory approval. [3] The provision covers approvals in the Philippines and in other countries. [13]<\/p>\n\n\n\n

        An article published in 2009 estimated that approval took about three years and argued that the provision removes an artificial delay. [13] That is an author’s estimate, not a regulatory figure.<\/p>\n\n\n\n

        How Long Does Generic Registration Take?<\/strong><\/h3>\n\n\n\n

        The FDA’s published process for initial registration of prescription generics lists a total of 120 working days. That total includes 20 working days of queuing, 50 working days of evaluation, and about 40 working days of supervisory review. [17] Analysis: 120 working days is about 24 weeks, or about 5.5 months.<\/p>\n\n\n\n

        In February 2024, news reports quoted FDA chief Samuel Zacate on a plan to cut generic drug facilitation from 120 days to 45 days. [18] That is an announced target. We did not find a confirmed implementation date, so the model treats it as unconfirmed.<\/p>\n\n\n\n

        How Long Does a Certificate of Product Registration Last?<\/strong><\/h4>\n\n\n\n

        The FDA document lists a choice of two-year or five-year validity. [17] The document does not state a date, so check for later FDA circulars before relying on these terms.<\/p>\n\n\n\n

        How Are Biologics and Biosimilars Treated?<\/strong><\/h3>\n\n\n\n

        Chambers reports that biosimilars can infringe the reference biologic’s patents on composition or production methods. It also reports no specific data or regulatory exclusivity rules for biologics or biosimilars. Marketing authorization follows Administrative Order 2024-0013. [8] The Philippines has no patent linkage for biologics either. [8]<\/p>\n\n\n\n

        Beyond the Patent: Parallel Imports, Compulsory Licenses, and Government Use<\/strong><\/h2>\n\n\n\n

        Can Parallel Imports of a Patented Drug Enter the Philippines?<\/strong><\/h3>\n\n\n\n

        Yes, in defined cases. Section 72.1 of the IP Code, as amended, limits the patent owner’s rights once a drug has been introduced “in the Philippines or anywhere else in the world by the patent owner.” Importation can be done by a government agency or a private third party. [3] Chambers says the same: a parallel import is not infringing if the patent holder or an authorized party first marketed the product. [4]<\/p>\n\n\n\n

        When Can a Compulsory License Be Granted?<\/strong><\/h3>\n\n\n\n

        The IPOPHL reply to a WIPO questionnaire lists grounds that include national emergency, public interest including health, anti-competitive practices, and non-working. [19] A non-working license cannot be sought before four years from filing or three years from grant, whichever expires last. Importation counts as working. [19]<\/p>\n\n\n\n

        Section 93-A allows a special compulsory license for drug imports. The IPOPHL Director General grants it on the written recommendation of the Secretary of Health, and it is primarily for domestic consumption. [3] The patent owner receives adequate remuneration. [19] The IPOPHL reply was filed in May 2012, so later amendments may not appear. [19]<\/p>\n\n\n\n

        What Is Government Use Under Section 74?<\/strong><\/h3>\n\n\n\n

        Section 74 lets the government use a patented invention in listed cases. For drugs and medicines, one listed case is a national emergency or other circumstance of extreme urgency. Another is that demand for the patented article is not met to an adequate extent and on reasonable terms. [3]<\/p>\n\n\n\n

        Price Regulation After Generic Entry: EO 104 and EO 155<\/strong><\/h2>\n\n\n\n

        Which Drugs Have Maximum Retail Prices?<\/strong><\/h3>\n\n\n\n

        Executive Order 104 of 2020 imposed maximum retail and wholesale prices on 87 drug molecules, covering 133 formulas. Executive Order 155, signed on December 7, 2021, added 34 molecules and 71 formulas. [20] Analysis: if the two lists do not overlap, the two orders together cover 121 molecules.<\/p>\n\n\n\n

        What Labeling Rule Applies?<\/strong><\/h4>\n\n\n\n

        EO 155 requires the maximum retail price to appear on the label with the words “RETAIL PRICE NOT TO EXCEED” and “UNDER DRUG PRICE REGULATION” on a red strip. [20] The DOH reviews the price list with the Department of Trade and Industry six months after the order takes effect, then every six months. [20]<\/p>\n\n\n\n

        Why Does Price Regulation Matter for Opportunity Sizing?<\/strong><\/h3>\n\n\n\n

        A generic entry model that assumes free pricing can overstate revenue for a covered molecule. Section 17 of Republic Act 9502 lets the President, on the Health Secretary’s recommendation, impose maximum retail prices on any drug or medicine. [3] Chambers adds that marketing authorization and pricing decisions are not linked to patent status. [4] Check the current price list for your molecule before you build revenue scenarios.<\/p>\n\n\n\n

        What the IPOPHL Numbers Show About Who Holds Philippine Patents<\/strong><\/h2>\n\n\n\n

        How Many Patents Did IPOPHL Receive and Grant From 2020 to 2024?<\/strong><\/h3>\n\n\n\n

        The table reproduces IPOPHL totals from the WIPO statistics page. [11] The page names pharmaceuticals as the leading technology field for filings, but it gives no pharmaceutical-specific counts. [11]<\/p>\n\n\n\n

        Year<\/th>Total filings<\/th>PCT filings<\/th>Total grants<\/th><\/tr><\/thead>
        2020<\/td>3,667<\/td>2,977<\/td>930<\/td><\/tr>
        2021<\/td>4,032<\/td>3,361<\/td>1,331<\/td><\/tr>
        2022<\/td>4,410<\/td>3,679<\/td>1,335<\/td><\/tr>
        2023<\/td>4,530<\/td>3,600<\/td>1,583<\/td><\/tr>
        2024<\/td>4,172<\/td>3,107<\/td>2,063<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

        What Do the Derived Shares Show?<\/strong><\/h4>\n\n\n\n

        Analysis: PCT applications were 74.5 percent of 2024 filings (3,107 of 4,172). Non-resident applicants received 1,958 of 2,063 grants in 2024, or 94.9 percent. Resident applicants received 105, or 5.1 percent. Total grants rose 30.3 percent from 2023 to 2024, from 1,583 to 2,063. [11]<\/p>\n\n\n\n

        \n

        “Grants rose 30% in 2024, to 2,063 from 1,583.” (IPOPHL statistics, as reproduced by the WIPO Centre for the Study of Patent Information) [11]<\/p>\n<\/blockquote>\n\n\n\n

        What Are the Data Limits?<\/strong><\/h3>\n\n\n\n

        The grant table does not report a PCT row after 2021. We therefore compare shares for 2024 only. We do not compare non-resident grant counts across years, because the row structure changed. The page also contains a typographical error in its filing sentence, which gives “2024” where the figures refer to 2023. We used the table values, not the sentence. [11]<\/p>\n\n\n\n

        The grant figures cover all technology fields. They do not tell you how many drug patents the office granted.<\/p>\n\n\n\n

        What This Means for Generic Manufacturers, Brand Owners, and Investors<\/strong><\/h2>\n\n\n\n

        What This Means for Generic Manufacturers<\/strong><\/h3>\n\n\n\n

        Start with the Philippine record, not the US record. If no Philippine patent exists, the barrier is regulatory only. If one exists, the 20-year date from the international filing date is the base case. Section 72.4 lets you prepare the filing before that date. [3] The FDA does not link approval to patents, so your own freedom-to-operate review must carry that risk. [4]<\/p>\n\n\n\n

        What This Means for Brand Manufacturers<\/strong><\/h3>\n\n\n\n

        You carry the monitoring burden. The FDA does not notify patentees of potentially infringing registrations. [4] A brand owner without a Philippine filing has no Philippine patent right, and US registrations do not protect IP in the Philippines. [21] The 30-month national phase deadline is fixed, with a one-month fee-based extension. [9]<\/p>\n\n\n\n

        What This Means for Investors and Business Development Teams<\/strong><\/h3>\n\n\n\n

        A market-entry model that imports the US expiration date will misstate the Philippine opening date in both directions. It will be too late for families where the US patent carries extension. It will be too early for families where a Philippine patent on a later filing exists and was granted. Run the four scenarios in this article for each product, then replace the assumptions with record data.<\/p>\n\n\n\n

        How to Verify the Philippine Patent Status of a Drug<\/strong><\/h2>\n\n\n\n

        Use the checklist below in order.<\/p>\n\n\n\n

          \n
        1. Identify the international filing date and publication date of the family from the PCT record.<\/li>\n\n\n\n
        2. Check whether the family entered the Philippine national phase within 30 months of priority, and whether the applicant requested substantive examination within six months. [9]<\/li>\n\n\n\n
        3. Check the IPOPHL record for grant, annual fee payment, and any cancellation proceeding.<\/li>\n\n\n\n
        4. Calculate the 20-year date and compare it to the US date, including adjustment, extension, and pediatric exclusivity. [5][6][7]<\/li>\n<\/ol>\n\n\n\n

          Where Does DrugPatentWatch Fit?<\/strong><\/h3>\n\n\n\n

          DrugPatentWatch states that it covers 134 countries and uses sources that include the FDA Orange Book, USPTO data, ANDA filings, and litigation records. [22] A platform of that kind gives you the US baseline and the family structure, which are steps one and four of the checklist. It does not replace the IPOPHL record for Philippine legal status. Confirm the Philippine record at the source before you act on any date.<\/p>\n\n\n\n

          Key Takeaways<\/strong><\/h2>\n\n\n\n
            \n
          • The Philippine patent term is a uniform 20 years, with no SPC and no pediatric extension. [8]<\/li>\n\n\n\n
          • A US patent can outlast the Philippine patent for the same family through adjustment, extension, and pediatric exclusivity. [5][6][7]<\/li>\n\n\n\n
          • In the Drug X model, the US date falls 24 months after the Philippine date, or 30 months with pediatric exclusivity. This is analysis based on stated assumptions.<\/li>\n\n\n\n
          • The Philippines has no patent linkage, and the FDA can register generics without a patent check. [4]<\/li>\n\n\n\n
          • Section 22.1 limits patents on new forms of known drugs unless they enhance known efficacy. [3][2]<\/li>\n\n\n\n
          • A Philippine patent may not exist if the applicant missed the 30-month national phase deadline. [9]<\/li>\n\n\n\n
          • The Lipitor family had US patent expiries from 2010 to 2018, and the settlement used country-specific terms. [10]<\/li>\n\n\n\n
          • Maximum retail prices under EO 104 and EO 155 cover 121 molecules in total if the lists do not overlap (analysis from [20]).<\/li>\n<\/ul>\n\n\n\n

            FAQ<\/strong><\/h2>\n\n\n\n

            Does the Philippines extend drug patents for regulatory delay?<\/strong><\/h3>\n\n\n\n

            No. Chambers reports no SPC or similar extension system and no pediatric extension. [8]<\/p>\n\n\n\n

            Does the Philippines have patent linkage?<\/strong><\/h3>\n\n\n\n

            No. The FDA can process registrations without checking patents, and it does not notify patentees. [4]<\/p>\n\n\n\n

            Can a generic company make test batches before the patent expires?<\/strong><\/h3>\n\n\n\n

            Yes, for purposes reasonably related to regulatory submissions. This is Section 72.4 of the IP Code. [3]<\/p>\n\n\n\n

            How long does generic registration take at the Philippine FDA?<\/strong><\/h3>\n\n\n\n

            The FDA’s published process for initial prescription generics lists 120 working days. [17] A 45-day target was announced in 2024 news reports. [18]<\/p>\n\n\n\n

            What is the deadline to enter the Philippine national phase from a PCT filing?<\/strong><\/h3>\n\n\n\n

            The deadline is 30 months from the priority date, with a one-month extension available for a fee. [9]<\/p>\n\n\n\n

            Are parallel imports of patented drugs allowed?<\/strong><\/h3>\n\n\n\n

            Yes, if the patent owner or an authorized party introduced the product anywhere in the world. [3][4]<\/p>\n\n\n\n

            When can someone seek a compulsory license for non-working?<\/strong><\/h3>\n\n\n\n

            Not before four years from filing or three years from grant, whichever expires last. Importation counts as working. [19]<\/p>\n\n\n\n

            Is there data exclusivity for biologics in the Philippines?<\/strong><\/h3>\n\n\n\n

            Chambers reports no specific data or regulatory exclusivity rules for biologics or biosimilars. Marketing authorization follows Administrative Order 2024-0013. [8]<\/p>\n\n\n\n

            Which drugs have maximum retail prices?<\/strong><\/h3>\n\n\n\n

            EO 104 covers 87 molecules and EO 155 adds 34. The annexes list the drugs, so check the current DOH price list. [20]<\/p>\n\n\n\n

            How can a team spot a lapsed Philippine patent?<\/strong><\/h3>\n\n\n\n

            Check annual fee status. The first fee is due four years after the international publication date, and later fees fall due each anniversary. [9]<\/p>\n\n\n\n

            References<\/strong><\/h2>\n\n\n\n
              \n
            1. Pfizer Inc. (2012). Form 10-K for the fiscal year ended December 31, 2011<\/em>. U.S. Securities and Exchange Commission. https:\/\/www.sec.gov\/Archives\/edgar\/data\/0000078003\/000119312512085703\/d278590d10k.htm<\/li>\n\n\n\n
            2. Spruson & Ferguson. (2021, November 11). Patentability of known pharmaceutical substances in the Philippines<\/em>. https:\/\/www.spruson.com\/patents\/patentability-of-known-pharmaceutical-substances-in-the-philippines\/<\/li>\n\n\n\n
            3. Republic of the Philippines. (2008). Republic Act No. 9502, Universally Accessible Cheaper and Quality Medicines Act of 2008<\/em>. Senate of the Philippines. https:\/\/legacy.senate.gov.ph\/republic_acts\/ra%209502.pdf<\/li>\n\n\n\n
            4. Bejemino, M. L., Cruz, M. P., & Chua, E. K. (2026). Philippines: Law and practice. In Life Sciences and Pharma IP 2026<\/em>, pp. 166-167. Chambers and Partners. https:\/\/gpg-pdf.chambers.com\/life-sciences-pharma-ip-litigation-2026\/167\/<\/li>\n\n\n\n
            5. U.S. Code. (n.d.). 35 U.S.C. 154, Contents and term of patent; provisional rights<\/em>. Cornell Law School Legal Information Institute. https:\/\/www.law.cornell.edu\/uscode\/text\/35\/154<\/li>\n\n\n\n
            6. U.S. Code. (n.d.). 35 U.S.C. 156, Extension of patent term<\/em>. Cornell Law School Legal Information Institute. https:\/\/www.law.cornell.edu\/uscode\/text\/35\/156<\/li>\n\n\n\n
            7. U.S. Food and Drug Administration. (n.d.). Frequently asked questions on patents and exclusivity<\/em>. https:\/\/www.fda.gov\/drugs\/development-approval-process-drugs\/frequently-asked-questions-patents-and-exclusivity<\/li>\n\n\n\n
            8. Bejemino, M. L., Cruz, M. P., & Chua, E. K. (2026). Philippines: Law and practice. In Life Sciences and Pharma IP 2026<\/em>, pp. 167-168. Chambers and Partners. https:\/\/gpg-pdf.chambers.com\/life-sciences-pharma-ip-litigation-2026\/168\/<\/li>\n\n\n\n
            9. Federis & Associates. (n.d.). What types of protection are available in the Philippines for a Patent Cooperation Treaty (PCT) application?<\/em> https:\/\/federislaw.com.ph\/faqs-resources\/patent-pct-philippines<\/li>\n\n\n\n
            10. BioSpace. (2008, June 18). Pfizer Inc. and Ranbaxy Laboratories settle Lipitor patent dispute; generic Lipitor to be launched Nov. 2011<\/em>. https:\/\/www.biospace.com\/pfizer-inc-and-ranbaxy-laboratories-settle-lipitor-patent-dispute-generic-lipitor-to-be-launched-nov-2011<\/li>\n\n\n\n
            11. World Intellectual Property Organization. (2024). CWS ATR PI 2024 PH<\/em> (IPOPHL patent statistics). https:\/\/confluence.wipo.int\/confluence\/spaces\/ATR\/pages\/1640671095\/CWS+ATR+PI+2024+PH<\/li>\n\n\n\n
            12. U.S. Code. (n.d.). 21 U.S.C. 355, New drugs<\/em>. Cornell Law School Legal Information Institute. https:\/\/www.law.cornell.edu\/uscode\/text\/21\/355<\/li>\n\n\n\n
            13. IPlaw.ph. (2009). The Bolar exception: Roots and introduction to the Philippine patent system<\/em>. https:\/\/iplaw.ph\/ip-views\/the-bolar-exception-roots-and-introduction-to-the-philippine-patent-system\/<\/li>\n\n\n\n
            14. Intellectual Property Office of the Philippines, Bureau of Legal Affairs. (2012, March 5). OEP Philippines, Inc. v. SmithKline Beecham PLC<\/em>, IPC No. 11-2008-00048. https:\/\/www.federislaw.com.ph\/wp-content\/uploads\/2014\/04\/OEP-PHILIPPINES-INC.-vs.-SMITHKLINE-BEECHAM-PLC-IPC-No.-11-2008-00048-March-05-2012.pdf<\/li>\n\n\n\n
            15. IPlaw.ph. (n.d.). Case digest: Pharmawealth vs. Pfizer (patent infringement)<\/em>. https:\/\/iplaw.ph\/ip-views\/case-digest-pharmawealth-vs-pfizer-patent-infringement\/<\/li>\n\n\n\n
            16. Supreme Court of the Philippines. (2010, November 17). Phil. Pharmawealth, Inc. v. Pfizer, Inc. and Pfizer (Phil.) Inc.<\/em>, G.R. No. 167715. https:\/\/batasnatin.com\/laws\/gr-167715<\/li>\n\n\n\n
            17. Philippine Food and Drug Administration. (n.d.). Certificate of Product Registration (CPR) of pharmaceutical products (initial, prescription generic drugs)<\/em>. https:\/\/www.fda.gov.ph\/wp-content\/uploads\/2023\/08\/5.-Pharma-Generics.pdf<\/li>\n\n\n\n
            18. GMA News. (2024, February). Marcos orders FDA to streamline PH drug application process<\/em>. https:\/\/gmanetwork.com\/news\/topstories\/nation\/897297\/marcos-orders-fda-to-streamline-ph-drug-application-process\/story<\/li>\n\n\n\n
            19. Intellectual Property Office of the Philippines. (2012, May). Reply to the WIPO SCP questionnaire on exceptions and limitations to patent rights<\/em>. World Intellectual Property Organization. https:\/\/www.wipo.int\/en\/web\/scp\/electronic-forum\/exceptions\/replies\/philippines<\/li>\n\n\n\n
            20. Republic of the Philippines. (2021, December 7). Executive Order No. 155, Further improving access to healthcare through the regulation of prices in the retail of drugs and medicines<\/em>. Lawphil. https:\/\/lawphil.net\/executive\/execord\/eo2021\/eo_155_2021.html<\/li>\n\n\n\n
            21. U.S. International Trade Administration. (2026, June 30). Philippines: Protecting intellectual property<\/em>. https:\/\/www.trade.gov\/knowledge-product\/philippines-protecting-intellectual-property<\/li>\n\n\n\n
            22. DrugPatentWatch. (n.d.). Home page<\/em>. https:\/\/www.drugpatentwatch.com\/<\/li>\n<\/ol>\n","protected":false},"excerpt":{"rendered":"

              Pfizer lost US exclusivity on Lipitor on November 30, 2011. [1] The EU compound patent for the same drug expired […]<\/p>\n","protected":false},"author":1,"featured_media":39933,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_lmt_disableupdate":"","_lmt_disable":"","site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[10],"tags":[],"class_list":["post-39932","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-insights"],"modified_by":"DrugPatentWatch","_links":{"self":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39932","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/comments?post=39932"}],"version-history":[{"count":1,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39932\/revisions"}],"predecessor-version":[{"id":39934,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/posts\/39932\/revisions\/39934"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media\/39933"}],"wp:attachment":[{"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/media?parent=39932"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/categories?post=39932"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.drugpatentwatch.com\/blog\/wp-json\/wp\/v2\/tags?post=39932"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}